Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy
- PMID: 19154404
- PMCID: PMC11159961
- DOI: 10.1111/j.1349-7006.2008.01065.x
Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy
Abstract
Resistance of ovarian mucinous adenocarcinoma to standard chemotherapy with paclitaxel and carboplatin is associated with poor prognosis, and an effective treatment is needed. The present study aimed to identify an effective chemotherapy for ovarian mucinous adenocarcinoma. Five human ovarian mucinous adenocarcinoma cell lines (MN-1, OMC-1, RMUG-L, RMUG-S, TU-OM-1) were used in this study. Sensitivity of the cells to the anticancer agents was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and we assessed drug sensitivity by calculating the assay area under the curve for each agent. Protein expression was confirmed by Western blot analysis. We also examined the efficacy of combination chemotherapy on survival in a xenograft model of nude mice. The IC(50) to anticancer agents ranged widely. The assay area under the curve indicated that two of five cell lines (MN-1, TU-OM-1) were sensitive to oxaliplatin, 5-fluorouracil and etoposide, and only one (TU-OM-1) was sensitive to 7-ethyl-10-hydroxycamptothecin, which is an active metabolite of camptothecin. All cell lines were resistant to cisplatin and paclitaxel. The combination of oxaliplatin and 5-fluorouracil resulted in additive or synergistic effects on all cell lines. The combination of oxaliplatin and 5-fluorouracil significantly prolonged survival in a ovarian mucinous adenocarcinoma xenograft model of nude mice. Protein expression levels of the excision repair cross-complementation group 1 were lower in oxaliplatin sensitive cell lines. Exposure to 5-fluorouracil down-regulated cross-complementation group 1 expression in ovarian mucinous adenocarcinoma cells. We conclude that combination chemotherapy consisting of oxaliplatin and 5-fluorouracil was an effective treatment for ovarian mucinous adenocarcinoma and may be a pivotal candidate for a novel treatment strategy.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11159961/bin/CAS-100-546-g003.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11159961/bin/CAS-100-546-g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11159961/bin/CAS-100-546-g001.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11159961/bin/CAS-100-546-g004.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11159961/bin/CAS-100-546-g005.gif)
Similar articles
-
Targeting SRC in mucinous ovarian carcinoma.Clin Cancer Res. 2011 Aug 15;17(16):5367-78. doi: 10.1158/1078-0432.CCR-10-3176. Epub 2011 Jul 7. Clin Cancer Res. 2011. PMID: 21737505 Free PMC article.
-
Targeting SRC and tubulin in mucinous ovarian carcinoma.Clin Cancer Res. 2013 Dec 1;19(23):6532-43. doi: 10.1158/1078-0432.CCR-13-1305. Epub 2013 Oct 7. Clin Cancer Res. 2013. PMID: 24100628 Free PMC article.
-
Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.Int J Gynecol Cancer. 2014 Mar;24(3):444-53. doi: 10.1097/IGC.0000000000000091. Int J Gynecol Cancer. 2014. PMID: 24552895
-
Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.Drugs. 2000 Oct;60(4):895-924. doi: 10.2165/00003495-200060040-00005. Drugs. 2000. PMID: 11085200 Review.
-
Platinum compounds in the treatment of advanced breast cancer.Clin Breast Cancer. 2001 Oct;2(3):190-208; discussion 209. doi: 10.3816/CBC.2001.n.022. Clin Breast Cancer. 2001. PMID: 11899413 Review.
Cited by
-
Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours.BMC Cancer. 2023 Jan 13;23(1):44. doi: 10.1186/s12885-023-10533-x. BMC Cancer. 2023. PMID: 36639622 Free PMC article.
-
Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates.Oncotarget. 2022 Mar 24;13:553-575. doi: 10.18632/oncotarget.28220. eCollection 2022. Oncotarget. 2022. PMID: 35359749 Free PMC article. Review.
-
Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas.Cancers (Basel). 2021 Dec 4;13(23):6120. doi: 10.3390/cancers13236120. Cancers (Basel). 2021. PMID: 34885229 Free PMC article. Review.
-
Options for the Treatment of Mucinous Ovarian Carcinoma.Curr Treat Options Oncol. 2021 Nov 13;22(12):114. doi: 10.1007/s11864-021-00904-6. Curr Treat Options Oncol. 2021. PMID: 34773517 Review.
-
Heterotargeted Nanococktail with Traceless Linkers for Eradicating Cancer.Adv Funct Mater. 2019 Dec 12;29(50):1906433. doi: 10.1002/adfm.201906433. Epub 2019 Sep 16. Adv Funct Mater. 2019. PMID: 33041742 Free PMC article.
References
-
- McGuire V, Jesser CA, Whittemore AS. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 2002; 84: 399–403. - PubMed
-
- Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003; 27: 985–93. - PubMed
-
- Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008; 109: 370–6. - PubMed
-
- Hess V, A’Hern R, Nasiri N et al . Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004; 22: 1040–4. - PubMed
-
- Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519–29. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials